Why the study?
What is the toxicity profile and response rate of high-dose liposome-encapsulated doxorubicin with G-CSF in patients with metastatic breast cancer?
Population
52 patients with advanced breast cancer, bidimensionally measurable metastatic disease, and no prior…
Design
Cohort
Authors
Loading...
High cardiotoxicity rates warrant caution with this regimen; leaves open the need for randomized safety data in metastatic breast cancer.
What is the toxicity profile and response rate of high-dose liposome-encapsulated doxorubicin with G-CSF in patients with metastatic breast cancer?
High-dose liposome-encapsulated doxorubicin provides no added therapeutic benefit but causes a high rate of cardiotoxicity, particularly in patients with prior adjuvant doxorubicin exposure.
Shapiro et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: